TFX 8-K SEC Filing Analysis

Latest settled — T+5d

TFX ▲ +1.66% at T+5d

NEUTRAL call ✓ call won +1.66% · α vs SPY +1.34% · entry $128.90 → $131.04

Next anchor: T+20d in 10d

Last close $130.48 (close Jun 12) · +1.22% from $128.90 entry

Entry anchored
May 27, 2026
via day open

T+1d

-0.28%

call -0.28% · α -0.52%

$128.54

settled 18d ago

T+5d

+1.66%

call +1.66% · α +1.34%

$131.04

settled 12d ago

T+20d

—

call — · α —

—

in 10d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Teleflex refinanced its existing credit facility by entering into a new $2.2 billion Credit Agreement on May 26, 2026. The new facility includes a $1.0 billion five-year revolving credit facility (maturing May 2031), a $500 million term A-1 loan (maturing May 2031), and a $700 million term A-2 loan (maturing May 2028). The agreement refinances the prior November 2022 credit agreement and contains financial covenants requiring a maximum total net leverage ratio of 4.50x and a minimum interest coverage ratio of 3.00x, with customary terms for a large, investment-grade credit profile medical device company.

Actionable Insight

This is a routine refinancing that extends maturity profiles and likely improves pricing terms versus the prior facility. The transaction does not change Teleflex's total debt or equity. Monitor upcoming quarterly filings for the impact of the pending Acute Care and OEM divestitures (announced Dec 2025) on leverage and the new covenant headroom.

Key Facts

Total new credit commitments of $2.2 billion: $1.0B revolver, $500M Term A-1, $700M Term A-2
Revolver and Term A-1 mature May 26, 2031 (5-year); Term A-2 matures May 26, 2028
Interest rates: Term SOFR + 1.125%-2.00% or ABR + 0.125%-1.00% based on leverage/ratings
Financial covenants: max total net leverage ratio 4.50x; min interest coverage ratio 3.00x
Refinances the prior Third Amended and Restated Credit Agreement dated Nov 4, 2022
Secured by substantially all domestic material subsidiary assets and pledges of equity

Financial Impact

Refinancing of $2.2 billion in credit facilities. Proceeds used to repay existing indebtedness. No new incremental borrowing or change in total debt size disclosed.

leverageliquiditydebt_maturity_profile

Risk Factors

Pending divestitures of Acute Care and OEM businesses could temporarily increase leverage post-closing
Future use of the $700M Term A-2 (maturing 2028) creates a refinancing risk in ~2 years

Market Snapshot

Exchange

NYSE

Sector

Surgical & Medical Instruments & Apparatus

Analyst Consensus

29% bullish (17 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001193125-26-242184
Document: d126197d8k.htm	0001193125-26-242184
Document: 0001193125-26-242184-index-headers.html	0001193125-26-242184
Document: 0001193125-26-242184-index.html	0001193125-26-242184
Document: 0001193125-26-242184.txt	0001193125-26-242184

5 reports for TFX

T+1T+5T+20T+60

Filters

Reports for TFX — sortable, filterable
	Type				Now
Jun 9, 2026 5d ago	8-K NEUTRAL ★ 2/10	$135.61 awaiting T+5	awaiting T+5	—	$130.48 (−3.78%)
Jun 1, 2026 13d ago	8-K NEUTRAL ★ 4/10	$127.31 $129.84	▲ +1.98%	▲ +4.73%	$130.48 (+2.49%)
May 27, 2026 18d ago	8-K NEUTRAL ★ 4/10	$128.90 $131.04	▲ +1.66%	▲ +1.34%	$130.48 (+1.22%)
May 7, 2026 5w ago	8-K MIXED ★ 6/10	$131.59 $130.04	▼ −1.18%	▼ −2.69%	$130.48 (−0.85%)
Feb 26, 2026 15w ago	8-K MIXED ★ 7/10	$118.39 $116.75	▼ −1.39%	▼ −0.26%	$130.48 (+10.21%)

US Market Status

Market Closed — Opens in 5h 11m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access